Tay Therapeutics

Tay Therapeutics is a biotechnology company that develops novel small-molecule treatments for oncology and severe genetic disorders. Tay Therapeutics was spun out from the world-leading School of Life Sciences at the University of Dundee and has laboratory facilities in Dundee, Scotland. Following the divestment of the BET inhibitor program, Tay Therapeutics will now focus on developing a platform to discover and develop a new class of drugs that can cause the body to ignore premature termination codon (PTC) mutations that lead to full-length functional proteins. By restoring functional proteins, our drugs aim to address the root causes of these diseases.